Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis

References

• Cancer Facts & Figures 2016. 2017; https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/estimated-number-of-new-cancer-cases-and-deaths-by-sex-us-2017.pdf
   Google Scholar
• Proctor S, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Criti Rev Oncol/Hematol. 2009;71:222–232.
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Wilkinson J, Jones G. Prospective evaluation of treatment outcome in 175 patients with Hodgkin Lymphoma (HL) aged sixty years or over: the SHIELD Study. Blood. 2012;119(25):6005–6015.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–695.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161:76–86.
   PubMed Web of Science ®Google Scholar
• Erdkamp FL, Breed WP, Bosch LJ, et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer. 1992;70:830–834.
   PubMed Web of Science ®Google Scholar
• Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 1993;71:1857–1866.
   PubMed Web of Science ®Google Scholar
• Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31(12):1522–1529.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016;127(18):2189–2192.
   PubMed Web of Science ®Google Scholar
• Klimm B, Eich H, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol. 2006;18:357–363.
   PubMedGoogle Scholar
• Evens AM, Hong F. How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol. 2013;31:1502–1505.
   PubMed Web of Science ®Google Scholar
• Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology. 2008;22:1369.
   PubMed Web of Science ®Google Scholar
• National Cancer Data Base. https://www.facs.org/quality%20programs/cancer/ncdb. Accessed September 1, 2015.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
   PubMedGoogle Scholar
• Perme MP, Pavlic K. Package “relsurv.” Available from: https://cran.r-project.org/package=relsurv. Published 2017.
   Google Scholar
• GHSG Disease Stages and Risk Factors. http://en.ghsg.org/disease-stages. Accessed November 1, 2017.
   Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:608–638.
   PubMedGoogle Scholar
• Meyer RM, Gospodarowicz MK, Connors JM. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–4642.
   PubMed Web of Science ®Google Scholar
• Fermé C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357:19.
   Web of Science ®Google Scholar
• Enblad G, Gustavsson A, Sundström C, et al. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncologica (Stockholm, Sweden). 2002;41:659–667.
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88:438–444.
   PubMed Web of Science ®Google Scholar
• Ballova V, Rüffer J-U, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124–131.
   PubMed Web of Science ®Google Scholar
• Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Jco. 2005;23:5052–5060.
   PubMedGoogle Scholar
• Feltl D, Vítek P, Zámečník J. Hodgkin's lymphoma in the elderly: the results of 10 years of follow-up. Leuk Lymphoma. 2006;47:1518–1522.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:570–576.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111:2977–2983.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126:2798–2804.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170:179–184.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55:2328–2334.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Eng J Med. 2018;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18:1611–1618.
   PubMed Web of Science ®Google Scholar
• Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02758717?term=nivolumab±hodgkin±lymphoma&rank=1. Accessed September 19, 2016.
   Google Scholar